Immunovia AB (publ) (STO:IMMNOV)

Market Cap	124.31M -7.7%
Revenue (ttm)	920.00K +0.7%
Net Income	-106.56M
EPS	-0.24
Shares Out	672.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1870
Previous Close	0.1872
Day's Range	0.1810 - 0.1906
52-Week Range	0.1502 - 0.9680
Beta	2.69
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 17
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IMMNOV

Financial Performance

In 2025, Immunovia AB's revenue was 685,000, a decrease of -26.42% compared to the previous year's 931,000. Losses were -145.92 million, 90.6% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 17, 2026

Data Sources Report a data error